Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationPaul B. Chapman, Grant A. McArthur, Axel Hauschild et al.|New England Journal of Medicine|2011Cited by 7.7k
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged SkinF. Stephen Hodi, David E. Fisher, Christopher L. Corless et al.|Journal of Clinical Oncology|2013Cited by 594
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV MelanomaAxel Hauschild, Ulrich Keilholz, Sanjiv S. Agarwala et al.|Journal of Clinical Oncology|2009Cited by 545
Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced MelanomaSteven O’Day, Axel Hauschild|Journal of Clinical Oncology|2013Cited by 379
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory responseFernanda I. Arnaldez, Paolo A. Ascierto, Bingqing Fu et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 93